Clinical trials: High Bleeding Risk Patients
Postpartum Hemorrhage
Tranexamic Acid for the Prevention of Postpartum Haemorrhage
Use of tranexamic acid (TXA) for the prevention of postpartum haemorrhage (PPH) after cesarean section in high-risk patients ( a randomized control trial ).
- Trial name
- NCT04707950
- Testing
- Tranexamic Acid 100 milligram/Milliliter, Oxytocin
- Where
- 2 sites in Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Benha University
Gastrointestinal Hemorrhage
Predictive Role of Red Cell Distribution Width in Upper GI Bleeding Patients
Acute upper-gastrointestinal bleeding (UGIB) is a commonly encountered cause of admission in emergency department (ED). Early risk stratification allows appropriate therapy that may be helpful to advance the patient's morbidity…
- Trial name
- NCT03119987
- Testing
- Red cell distribution widths
- Volunteers
- 400 people
- Sponsor
- Konkuk University Medical Center
Atrial Fibrillation, Atrial Arrhythmia
Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients
The purpose of this multicenter study is to collect information from routine clinical practices for patients with left atrial appendage occlusion (LAAO) devices presenting for pulmonary vein isolation (PVI) or left atrial…
- Trial name
- PROCEED-AF (NCT07580937)
- Testing
- Data collection
- Where
- 20 sites in United States, Belgium and 7 more
- Volunteers
- 198 people
- Sponsor
- University of Chicago
Immune Thrombocytopenic Purpura
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment.
- Trial name
- NYMC207 (NCT04323748)
- Testing
- rituxan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Coronary Artery Disease
EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding
RATIONALE: Transradial coronary stenting is associated with less risk of access site complications and bleeding compared to femoral approach. Major bleeding post-PCI is a strong independent predictor of mortality and MACE.
- Trial name
- EASY-B2B (NCT01084993)
- Testing
- Bivalirudin, Heparin
- Where
- Canada
- Volunteers
- 2,000 people
- Sponsor
- Laval University
High Bleeding Risk, Hemorrhage
Efficacy of Intermittent Pneumatic Compression (IPC) on Venous Thromboembolism Incidence in Intensive Care Unit (ICU) Patients With High Bleeding Risk
This multicentre open-label randomized parallel-group trial aims to evaluate the association intermittent pneumatic compression + elastick stockings versus elasting stockings alone on symptomatic or asymptomatic venous…
- Trial name
- CIREA1 (NCT00740844)
- Testing
- Intermittent pneumatic compression of the lower limbs
- Where
- 10 sites in France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Brest
Post Partum Haemorrhage, Maternal Care Patterns
Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage
Oli is a predictive, non-invasive device, intended to be placed on the participant's maternal abdomen during the intrapartum period, which can alert healthcare professionals of an impending cumulative blood loss of ≥500 ml…
- Conditions
- Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
- Trial name
- NCT06655207
- Testing
- Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding
- Where
- 7 sites in United States, Australia
- Volunteers
- 1,000 people
- Sponsor
- Baymatob Operations Pty Ltd
Bleeding, Thrombosis
Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery
Patients who have undergone placement of coronary stents require dual antiplatelet therapy with Plavix and aspirin to prevent the serious complication of in-stent thrombosis.
- Trial name
- NCT00653601
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Coronary Disease, Drug Eluting Stent
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal…
- Conditions
- Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03287167
- Testing
- 1 month DAPT, 6 months DAPT
- Where
- China
- Volunteers
- 1,720 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Compensated Advanced Chronic Liver Disease, Variceal Hemorrhage
Spleen Stiffness Combined With Liver Stiffness Measured by 2D-SWE for the Screening of High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS2004)
Variceal hemorrhage is the serious complication in patients with compensated advanced chronic liver disease (cACLD). To evaluate the bleeding risk of varices, esophagogastroduodenoscopy (EGD) should be performed.
- Trial name
- NCT04546360
- Testing
- Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.
- Where
- 6 sites in China
- Volunteers
- 381 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Portal Vein Thrombosis, Anticoagulant Therapy
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis…
- Conditions
- Portal Vein Thrombosis, Anticoagulant Therapy, Variceal Bleeding
- Trial name
- NCT07602062
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 175 people
- Sponsor
- Shanghai Zhongshan Hospital
Myocardial Infarction
Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction
Rationale: Heart attacks are a major cause of death and result from coronary blood clots that require acute coronary intervention and antithrombotic drugs to restore blood flow and prevent new heart attacks.
- Trial name
- Dan-DAPT (NCT05262803)
- Testing
- CYP2C19*2/*3, Shorter DAPT duration
- Where
- 6 sites in Denmark
- Volunteers
- 2,808 people
- Sponsor
- Rikke Sorensen
Coronary Artery Disease
A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients
The purpose of this study is to evaluate the clinical safety and effectiveness of the Resolute Onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable for more than 1 month DAPT treatment receiving…
- Trial name
- Onyx ONE (NCT03344653)
- Testing
- Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System, Biosensors BioFreedom BA9 Drug Coated Coronary Stent
- Where
- 89 sites in Australia, Austria and 21 more
- Volunteers
- 2,000 people
- Sponsor
- Medtronic Vascular
Proliferative Diabetic Retinopathy - High Risk
Immediate Postoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy
Patients undergoing surgery for complications related to diabetes will be recruited.
- Trial name
- Postop IVA (NCT06899529)
- Testing
- Bevacizumab
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Christian Ophthalmic Surgery Expedition Network
Atonic Postpartum Hemorrhage, High Risk Pregnancy
Carbetocin Versus Oxytocin for Prophylaxis Against Atonic Primary Post-partum Hemorrhage
Comparison between Carbetocin and Oxytocin as prophylaxis against Primary Postpartum Hemorrhage.
- Trial name
- NCT05479357
- Testing
- Oxytocin, Carbetocin
- Volunteers
- 80 people
- Sponsor
- Sohag University
Bleeding Complications
Clopidogrel Monotherapy in Patients With High Bleeding Risk
The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications.
- Trial name
- NCT05223335
- Testing
- Clopidogrel, Prasugrel, Tricagrelor
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ
Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
This phase II trial is studying the side effects and how well giving radiation therapy together with bevacizumab, paclitaxel, and carboplatin works in treating patients with unresectable stage IIIB or stage IV non-small cell lung…
- Conditions
- Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ, Hemoptysis, Squamous Cell Lung Cancer
- Trial name
- NCT00387374
- Testing
- bevacizumab, paclitaxel, carboplatin
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Coronary Artery Disease, Percutaneous Coronary Intervention
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- PROTECT-HBR (NCT04416581)
- Testing
- PPI, P-CAB 50
- Where
- 45 sites in South Korea
- Volunteers
- 3,320 people
- Sponsor
- Duk-Woo Park, MD
Chronic Coronary Syndrome
Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2
A prospective, multi-center, open-label, randomized controlled, and superiority trial. The trial will compare clinical outcomes between discontinuation of antiplatelet agent and continuation of antiplatelet agent in HBR patients…
- Trial name
- DCB-HBR-2 (NCT06742931)
- Testing
- Discontinuation of antiplatelet agent group, Continuation of antiplatelet agent group
- Where
- 18 sites in South Korea
- Volunteers
- 1,200 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI
The purpose of this study is to compare DCB with DES in stable CAD or ACS patients who are at high risk of bleeding. The hypothesis of the DEBATE trial is that the strategy using DCB and a shorter DAPT regimen is non-inferior to…
- Trial name
- DEBATE (NCT04814212)
- Testing
- Percutaneous coronary intervention using drug-coated balloon, Percutaneous coronary intervention using drug-eluting stent
- Where
- 14 sites in Finland, France and 2 more
- Volunteers
- 546 people
- Sponsor
- North Karelia Central Hospital